EGFR/CDK2-IN-3

HY-156115

EGFR/CDK2-IN-3

EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM[1].

Ask for quotation

HY-156114

EGFR/CDK2-IN-2

EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC50s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 0.39 μM[1].

Ask for quotation

HY-156116

EGFR/CDK2-IN-4

EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC50s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 2.74 μM[1].

Ask for quotation

MBS516871-5x001mg

EGFR (C797S L858R), Active

2097.5 €

ABC-KH4644

Human EGFR (C240Y/+) RKO Cell Line

Human EGFR (C240Y/+) RKO Cell line is Heterozygous knockin of EGFR point mutation (C240Y).

Ask for quotation

79428

EGFR (C775S T790M L858R), GST-Tag

Recombinant Human EGFR also known as ERBB, mENA, ERBB1, and HER1 with C775S, T790M, and L858R mutations. Genbank Accession NM_005228, a.a. 668-end, with an N-terminal GST-tag, expressed in Sf9 cells via a baculovirus expression system. MW = 100 kDa.

765 €